• Devices and Masks & Other revenue grew 8.7% and 10.7% respectively
• Residential Care Software revenue increased 6.0%
• Net income increased 11.9% year-over-year
• Declared quarterly dividend of $0.60 per share

ResMed Inc. reported its financial results for the first quarter of fiscal year 2026. The company saw strong growth across its Sleep and Breathing Health and Residential Care Software segments, with Devices revenue increasing 8.7% and Masks & Other revenue increasing 10.7% year-over-year. Residential Care Software revenue also grew 6.0% compared to the prior year period. Total revenue for the quarter was $1.34 billion, a 9.0% increase from the same period last year. Net income increased 11.9% to $348.5 million. The company continued to invest in research and development, with R&D expenses increasing 9.8% year-over-year. ResMed also returned capital to shareholders, declaring a quarterly dividend of $0.60 per share. Overall, ResMed delivered a solid performance in the first quarter, demonstrating the strength of its product portfolio and software offerings across its global markets.

For fiscal year 2026, ResMed expects revenue growth in the range of 8-10% and net income growth in the range of 10-12% compared to fiscal year 2025.

ResMed remains focused on driving innovation in its Sleep and Breathing Health and Residential Care Software businesses to meet the growing demand for its products and services. The company is well-positioned to continue its strong financial performance and deliver value to shareholders.